2026³â 05¿ù 05ÀÏ È­¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Crown Bioscience Appoints John Gu as Chief Executive Officer

´º½ºÀÏÀÚ: 2025-03-29

SAN DIEGO -- Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and a part of JSR Life Sciences and Japan-based JSR Corporation, has appointed John Gu as its new Chief Executive Officer (CEO). Following his tenure as interim CEO and his role as Chief Operating Officer (COO), John Gu is recognized as an esteemed leader with broad business acumen and extensive experience in digital strategy, business transformation, and genomic data analysis. His unparalleled experience is particularly relevant in streamlining AI-driven approaches to advance drug discovery and development processes, marking him as a remarkable asset in steering Crown Bioscience to the forefront of biotechnological innovation.

“Gu’s global perspective and commitment to collaboration and excellence have laid a strong foundation for visionary leadership,” said Tim Lowery, President of JSR Life Sciences, Crown Bioscience’s parent company. “His pivotal role will undoubtedly advance our mission to positively impact global patient health while steering the company towards greater success.”

Gu joined Crown Bioscience in 2020 as Chief Operating Officer after holding leadership roles at companies including Genuity Science (formerly WuXi Nextcode), Silver Sand Technologies, and Baidu. His impactful strategies in the advancement of global technology platforms and operations and client services have equipped him well for this leadership position.

“I am motivated by the shared vision and capabilities that form the backbone at Crown Bioscience,” said Gu. “Our collective efforts aim to set new benchmarks in oncology drug discovery, and enhance patient outcomes globally.”

As CEO (and continuing as COO), Gu will focus on growth by expanding the company’s offerings and global presence, enhancing operational efficiency, and strengthening partnerships to foster innovation. Under Gu’s leadership, Crown Bioscience is poised to significantly enhance its contributions to global human health, reinforcing its reputation for delivering an industry-leading portfolio of services and platforms that address the complex needs of its clients.



 Àüü´º½º¸ñ·ÏÀ¸·Î

Axelspace-Led Consortium Chosen for Japan Space Fund Project on Next-Gen Earth Observation Satellite Technology
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond
bet365 Partners with TestMu AI to Accelerate Global Release Velocity with Agentic AI Quality Engineering
Quectel Expands Mid-tier 5G Portfolio with New RedCap 3GPP Release 17 Variants
Takeda¡¯s Zasocitinib Shows Rapid, Durable Skin Clearance in Once-Daily Pill, Promising to Reshape Psoriasis Care
Regnology Announces Next-Generation Ascend Platform with Agentic AI, Advancing the Future of Regulatory Reporting
SS&C Unveils WorkHQ to Power Enterprise Agentic Automation

 

AI Ambitions at Risk as Only 14% of Enterprises Fully Realize Cloud Va...
Boomi Named a Leader in IDC MarketScape for Worldwide API Management 2...
Global PC Shipments Grew 3% in 1Q26 as Supply Chain Impacts Emerged
NBA Bounce Brings Action-Packed Basketball Fun to LG Electronics¡¯ Sma...
Laserfiche Introduces AI Agents: The Future of Intelligent Content Man...
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast t...
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio¡¯s NEOK002...

 


°øÁö»çÇ×
'º£³×ÀÍ' Áß¹® Ç¥±â 宝Ò¬ìÌ, 'À̺ñÁî: ÀÌÁö' Áß¹® Ç¥±â æ¶币òª...
¿¡³ÊÀ¯ Enereu 额Òö äþÒö
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´º½ºÁö Áß¹®Ç¥±â´Â À½Â÷ Ç¥±â¹æ½Ä '纽ÞÙó¢ ´Ï¿ì½ºÁö'
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®À¯ºñ Alliuv ä¹备: ä¹êó备, ¾Ë¶ã Althle ä¹÷åìÌ
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØ ä¹ì³ÜØ
´º½º±×·ì Á¤º¸ ¹Ìµð¾î ºÎ¹® »óÇ¥µî·Ï
¾ËÇÁ·Ò °è¿­ »óÇ¥, »óÇ¥µî·Ï ¿Ï·á

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..